NCT03657446 is a Phase 1 clinical trial of Clazosentan in Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd..

Who is sponsoring NCT03657446?

NCT03657446 is sponsored by Idorsia Pharmaceuticals Ltd..

What drugs are being tested in NCT03657446?

Interventions in NCT03657446: Clazosentan, Placebo, Moxifloxacin.

What condition does NCT03657446 study?

NCT03657446 studies Healthy Subjects.

Is NCT03657446 still recruiting?

NCT03657446 is currently completed. Last updated 20 November 2018.

Last reviewed 2018-11-20 · How we verify

NCT03657446

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function

Completed Phase 1 Last updated 20 November 2018

What this trial tests

Phase 1 trial testing Clazosentan in Healthy Subjects in 36 participants. Completed in 26 October 2018.

Timeline

18 September 2018

Primary endpoint
26 October 2018

26 October 2018

Quick facts

Lead sponsor	Idorsia Pharmaceuticals Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	other
Enrollment	36
Start date	18 September 2018
Primary completion	26 October 2018
Estimated completion	26 October 2018
Sites	1 location across Netherlands

Drugs / interventions tested

Clazosentan (CLAZOSENTAN) — full drug profile →
Placebo
Moxifloxacin (moxifloxacin) — full drug profile →

Conditions studied

Healthy Subjects — all drugs for Healthy Subjects →

Sponsor

Idorsia Pharmaceuticals Ltd. — full company profile →

Who can join

Adults 18 to 65, any sex, with Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will investigate whether administration of clazosentan can affect normal heart function in healthy subjects

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT.
Henrich A, Juif PE, Dingemanse J, Krause A. · · 2021 · cited 4× · PMID 33389549 · DOI 10.1007/s10928-020-09728-7

Verify or expand the search:

Other trials of Clazosentan

Trials testing the same drug.

NCT03585270 — Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the · Phase 3 · completed
NCT03596294 — A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan · Phase 1 · completed
NCT02560532 — Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal S · Phase 2 · completed
NCT00558311 — Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachno · Phase 3 · completed

Other recruiting trials for Healthy Subjects

Currently open trials in the same condition.

NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting

Other Idorsia Pharmaceuticals Ltd. trials

Trials by the same sponsor.

NCT06799884 — A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormo · Phase 1 · completed
NCT05877222 — A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in · Phase 1 · completed
NCT05597020 — A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia · Phase 4 · completed
NCT05632393 — A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women · Phase 1 · completed
NCT05702177 — A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03657446 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Idorsia Pharmaceuticals Ltd.
Last refreshed: 20 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03657446.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing